Home > Insider Trading > Filing (0001140361-22-034588)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1559053	Prothena Corp Public Ltd Co	PRTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1564380	G. Gene Kinney	C/O Prothena Biosciences Inc 331 Oyster Point Boulevard South San Francisco CA 94080	President And Ceo	No	No	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Ordinary Shares, Par Value $0.01 Per Share	Acquisiton	2022-09-21	2,720	$6.41	15,513	No	4	M	Direct
Ordinary Shares, Par Value $0.01 Per Share	Disposition	2022-09-21	2,720	$32.02	12,793	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Ordinary Shares	Stock Option (Right to Buy)	Disposition	2022-09-21	2,720	$0.00	2,720	$6.41

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
16,412		2023-01-29	No	4	M	Direct

Footnotes

The transactions reported in the Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person.
The transaction was executed in multiple trades in prices ranging from $32.00 to $32.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
The option was granted on January 29, 2013 and all shares subject to the option were fully vested and exercisable. The option will expire in approximately four months and be forfeited to the extent it is not exercised on or prior to January 29, 2023.
The Reporting Person holds options that give him the right to acquire an aggregate of 2,021,112 shares at exercise prices ranging from $6.41 to $32.45, of which 1,509,237 are currently exercisable, and 511,875 are currently unexercisable but vest over time, subject to the Reporting Person's continued employment with the Issuer on each applicable vesting date of each option award.